Quetiapine fumarate (QF) is an atypical antipsychotic, undergoing extensive first pass
metabolism and hence shows lower bioavailability orally. Solid Lipid Nanoparticles (SLNs) …

Quetiapine fumarate is an antipsychotic drug with poor oral bioavailability (9%) due to first‐
pass metabolism. Present work is an attempt to improve oral bioavailability of quetiapine …

Quatiepine, an effective atypical anti psychotic administered as fumarate or hemifumarate
salts by intravenous injection shows poor brain uptake due to low partitioning and/or Pgp …

Aims: The study aimed at developing and characterizing Nanostructured Lipid Carriers
(NLC) of Quetiapine Fumarate (QF) by Design of Experiment (DoE) for the enhancement of …

Background: Quetiapine fumarate, a 2nd generation anti-psychotic drug has oral
bioavailability of 9% because of hepatic first pass metabolism. Reports suggest that co …

Purpose The objective of this work was to develop a new nanostructured lipid carrier (NLC)
formulation for the oral delivery of quetiapine fumarate (QTF) and assess the drug's in vitro …

Abstract Aim: Nanostrucured Lipid Carriers (NLCs) are the 2nd generation of Solid Lipid
Nanoparticles (SLNs) designed to overcome limitations of SLNs. Their characteristics can be …

Background: Lymphatic route is one of the prominent routes for improving the poor
bioavailability of the drugs which undergo extensive hepatic first pass metabolism …

This study aims to investigate the changes in plasma pharmacokinetics and liver and brain
distribution of quetiapine (QTP) due to its encapsulation into a polymeric nanocarrier. For …

Quetiapine is an atypical antipsychotic used to treat schizophrenia. However, despite great
interest for its chronic therapeutic use, quetiapine has some important side effects such as …